---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Bispecific t-cell receptor therapy"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Bispecific t-cell receptor therapy. Topics: Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants; Tebentafusp: IMCgp100-202 control arm composition and dosing; Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis; Tebentafusp: IMCgp100-202 treatment beyond progression, crossover, and survival with progressive disease as best response at 3 years; 16 further topics. 20 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/bispecific-t-cell-receptor-therapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Bispecific t-cell receptor therapy

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Bispecific T-cell Receptor Therapy

<a id="topic-2.2.2.1.1-1"></a>

### Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants

> “A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.”
> “Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01).”
> “The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported.”

Source: [Nathan et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34551229/)

<a id="topic-2.2.2.1.1-2"></a>

### Tebentafusp: IMCgp100-202 control arm composition and dosing

> “Of the 378 eligible HLA-A*02:01–positive patients, 252 were randomly assigned to the tebentafusp group and 126 to the control group; of the patients in the control group, 103 (82%), 16 (13%), and 7 (6%) were assigned to receive pembrolizumab, ipilimumab, and dacarbazine, respectively (Fig. S1 in the Supplementary Appendix).”
> “Pembrolizumab was given intravenously at a dose of 2 mg per kilogram of body weight (with a maximum of 200 mg per dose) on day 1 of each 21-day cycle. Ipilimumab was administered intravenously at a dose of 3 mg per kilogram on day 1 of each 21-day cycle for a maximum of four doses. Dacarbazine was given intravenously at a dose of 1000 mg per square meter of body-surface area on day 1 of each 21-day cycle.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-3"></a>

### Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis

> “In this 3-year analysis, the overall survival benefit continued to favor tebentafusp, with a stratified hazard ratio for death of 0.68 (95% CI, 0.54 to 0.87) (Fig. 1A). Median overall survival was 21.6 months (95% CI, 19.0 to 24.3) in the tebentafusp group and 16.9 months (95% CI, 12.9 to 19.5) in the control group.”
> “The percentage of patients who were surviving at 1, 2, and 3 years among those treated with tebentafusp was 72%, 45%, and 27%, respectively, as compared with 60%, 30%, and 18% among the patients in the control group (Fig. 1A and Table S4).”
> “Median progression-free survival was 3.4 months (95% CI, 3.0 to 5.4) in the tebentafusp group and 2.9 months (95% CI, 2.8 to 3.0) in the control group (stratified hazard ratio for progression or death, 0.76; 95% CI, 0.60 to 0.97) (Fig. 1B and Table S4).”
> “With extended follow-up, the percentage of patients who had an objective response continued to be higher in the tebentafusp group than in the control group (11% vs. 5%), with five additional patients in the tebentafusp group having a partial response since the previous analysis (Table 1 and Fig. S5).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-4"></a>

### Tebentafusp: IMCgp100-202 treatment beyond progression, crossover, and survival with progressive disease as best response at 3 years

> “More than half the patients who received treatment in the tebentafusp group (139 of 245 [57%]) were treated beyond initial radiographic progression, as compared with a quarter of the patients in the control group (28 of 111 [25%]). Sixteen patients in the control group crossed over to receive tebentafusp after the primary analysis (Table S2).”
> “When this analysis was repeated with data from patients who crossed over to the tebentafusp group censored at the start of treatment with tebentafusp, the effect on the hazard ratio for death was minimal (0.70; 95% CI, 0.54 to 0.90).”
> “In a 100-day landmark analysis involving the patients who had a best overall response of progressive disease by day 100 after randomization, postlandmark overall survival was longer in the tebentafusp group than in the control group (Fig. 2, Table S6, and Figs. S8 and S9). The hazard ratio for death in this analysis was 0.62 (95% CI, 0.44 to 0.89) in favor of tebentafusp.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-5"></a>

### Tebentafusp: IMCgp100-202 cytokine release syndrome by ASTCT grade and treatment-related discontinuation at 3 years

> “cytokine release syndrome, which was graded post hoc, occurred in 89% of tebentafusp-treated patients and was most frequent in the first 4 weeks of treatment.”
> “Most of the patients who had cytokine release syndrome (88%) had grade 1 (12%) or 2 (76%) as the maximum grade, although some patients (1%) had a grade 3 event.”
> “Grade 3 or 4 treatment-related adverse events occurred in 116 patients (47%); the most common were rash (19%) and an elevation in the aspartate aminotransferase level (6%).”
> “No new treatment-related discontinuations were reported: during the trial, 2% of the patients in the tebentafusp group and 5% of those in the control group discontinued treatment because of adverse events that were related to treatment.”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.1-6"></a>

### Tebentafusp: IMCgp100-202 final 5-year overall survival

> “Patients assigned to tebentafusp showed a continued overall survival advantage at 5 years, with median overall survival of 21.6 versus 16.9 months for the control group (hazard ratio 0.67, 95% CI 0.54-0.85, Figure 1). The 5-year survival rate was 16% (95% CI 11-21) in the tebentafusp group and 8% (95% CI 4-14) in the control group.”
> “As most deaths were related to disease progression (91%), melanoma-specific survival was highly similar to the overall population with a hazard ratio of 0.69 (95% CI 0.54-0.88).”
> “Of patients surviving at least 5 years, 44% (11 of 25) in the tebentafusp group were reported to have only received tebentafusp, whereas 6 of 7 patients in the control group had received subsequent tebentafusp”
> “Despite an 11% overall response rate, tebentafusp conferred a meaningful survival advantage not explained by subsequent therapies and evident across all RECIST categories.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-7"></a>

### Tebentafusp: IMCgp100-202 survival with progression on tebentafusp and treatment beyond radiographic progression at 5 years

> “After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment.”
> “Overall survival in patients with a best overall response of progressive disease by day 100 after randomization continued to be longer in the tebentafusp group than in the control group after a minimum duration of follow-up of 5-years [hazard ratio 0.61 (95% CI 0.43-0.88)”
> “Although the effect of TBP cannot be determined with certainty in this study, after adjusting for differences in these covariates, continued tebentafusp treatment was associated with improved postprogression survival [hazard ratio 0.61 (95% CI 0.44-0.83); Figure 5], with a similar trend of benefit among patients whose best overall response was progressive disease [hazard ratio 0.67 (95% CI 0.44-1.01)].”
> “Additionally, after rebaselining tumor burden at the point of initial disease progression, 27% (38/139) of tebentafusp patients treated beyond PD had subsequent tumor reduction compared with only 4% (1/28) of patients in the control group.”
> “Notably, 22% of patients in the control group received subsequent tebentafusp.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-8"></a>

### HLA-A∗02:01 restriction: proportion of HLA-A∗02:01-negative patients at IMCgp100-202 prescreening

> “Furthermore, HLA-A∗02:01-negative patients continue to lack an established standard of care and comprised 49% of individuals prescreened, consistent with the rate observed in another ImmTAC study.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.1-9"></a>

### Tebentafusp in previously treated disease: IMCgp100-102 response and survival

> “Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria.”
> “More than two-thirds of patients (n = 90) received prior immune checkpoint inhibition, of whom 68% had primary resistance to treatment with a prior best response of progressive disease, and 32% relapsed, with a prior best response of at least stable disease, following treatment.”

Source: [Carvajal et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9671803/)

<a id="topic-2.2.2.1.1-10"></a>

### Tebentafusp in previously treated disease: IMCgp100-102 long-term survival in 146 treated participants

> “146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95% CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively.”

Source: [Sacco et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11163599/)

<a id="topic-2.2.2.1.1-11"></a>

### Cytokine release syndrome: incidence, grade, and timing in a pooled analysis of 391 participants from IMCgp100-102 and IMCgp100-202

> “Across both studies, most patients experienced at least one episode of CRS (n = 344 of 391; 88%), the majority of which were mild (grade 1, 19%) or moderate (grade 2, 67%) in severity (Fig. 2A; Supplementary Table S4). Most grade 2 CRS events (92%) were due to hypotension, whereas 4.5% of events were attributed to hypoxia and 3.6% involved both conditions. Only a few patients (n = 7, 2%) had grade 3 (n = 6) or grade 4 (n = 1) CRS.”
> “There were no instances of immune effector cell-associated neurotoxicity syndrome reported, and no deaths occurred as a result of CRS.”
> “Most patients experienced CRS after each of the first three tebentafusp infusions, but both incidence and severity decreased with repeated dosing (Supplementary Fig. S3A).”

Source: [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12666308/)

<a id="topic-2.2.2.1.1-12"></a>

### Cytokine release syndrome: management with antipyretics, fluids, and corticosteroids, and hospitalization in IMCgp100-202

> “Unlike other trials of T-cell engagers, none of the three tebentafusp trials mandated any premedications as primary prophylaxis for CRS. The medications most frequently used to treat CRS were antipyretics (88%), intravenous fluids (45%), and systemic corticosteroids (25%; Table 3); four (1%) patients received tocilizumab.”
> “Most patients with CRS (64%) received only a single dose of systemic corticosteroid to manage their CRS episodes, and in a post hoc propensity score analysis of IMCgp100-202, early corticosteroid use to manage AE did not negatively affect OS when adjusted for baseline prognostic factors (Fig. 3).”
> “In a retrospective analysis of hospitalizations, defined as either an extension of the mandated monitoring period during intra-patient dose escalation or an unplanned hospitalization at any time, in IMCgp100-202, a similar percentage of patients experienced an SAE-related hospitalization in the tebentafusp arm (24%) as in the investigator’s choice control arm (23%; Supplementary Table S8). In the tebentafusp group, most (65%) SAE-related hospitalizations occurred during the intra-patient dose-escalation period.”

Source: [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12666308/)

<a id="topic-2.2.2.1.1-13"></a>

### Cytokine release syndrome: expert recommendations for post-dose monitoring and patient selection

> “Patients in good clinical condition and with a low tumour burden are good candidates for tebentafusp treatment, particularly if treated as early as possible after the diagnosis of metastatic disease.”
> “Postdose monitoring should thus focus on pyrexia and hypotension as the first symptoms of cytokine release. To minimise the risk of hypotension associated with CRS, patients should receive intravenous fluids before starting treatment.”

Source: [Hassel et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/37595494/)

<a id="topic-2.2.2.1.1-14"></a>

### Tebentafusp: survival by line of therapy and inpatient stay during dose escalation in a treated cohort

> “71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12 months (range 0 to 34), mOS was 21 months (95% CI, 17 to NR), and mPFS was 2.76 months (95% CI, 2.53-3.22).”
> “First-line tebentafusp was associated with a longer mOS of 22 months (95% CI, 18 months to NR), compared to a mOS of 16 months (95% CI 10 months to NR) in the second-line and beyond (Figure S7).”
> “The required inpatient stay within the dose escalation phase was generally brief, with a median of 3 cumulative number of nights as an inpatient for doses 1 to 3.”
> “No ≥ grade 3 toxicity was observed beyond dose 5.”

Source: [Joseph et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13568816/)

<a id="topic-2.2.2.1.1-15"></a>

### Tebentafusp in a cohort of 175 participants: toxicity, treatment beyond progression, and survival

> “175 patients were included: 127 received first-line tebentafusp, 48 had prior immune checkpoint inhibitors and/or chemotherapy.”
> “Thirty-two patients (18 %) developed transient grade 3-4 toxicity, mostly rash, 5 patients had grade 3 cytokine release syndrome.”
> “76 patients (43 %) were treated beyond progression; 1 was the CR, 1 PR and 30 SD. Median progression-free survival (PFS) was 4 months (95 % CI 2.7-5.3), median OS was 20 months (95 % CI 15.3-24.6).”

Source: [van der Kooij et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40680464/)

<a id="topic-2.2.2.1.1-16"></a>

### Tebentafusp: retrospective comparison of sequencing with immune checkpoint inhibitors

> “Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by ICIs (group 1) or the inverse sequence (group 2) at any treatment line were retrospectively identified.”
> “Median OS was 22.4 months (95 % CI 19-24.8) in group 1 and 33.6 months (95 % CI 28.9-43) in group 2 (p = 0.004).”
> “This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.”

Source: [Dimitriou et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39647344/)

<a id="topic-2.2.2.1.1-17"></a>

### Tebentafusp versus nivolumab plus ipilimumab: propensity score-weighted comparison of IMCgp100-202 and GEM1402

> “In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%.”
> “The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.”
> “IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06).”

Source: [Piulats et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38048850/)

<a id="topic-2.2.2.1.1-18"></a>

### Tebentafusp: guideline recommendation for HLA-A∗02:01-positive metastatic disease

> “For HLA-A∗02:01-positive patients, tebentafusp should be standard of care in the first-line metastatic setting unless liver-directed treatment modalities are required first for tumour debulking [I, A; ESMO-Magnitude of Clinical Benefit (ESMO-MCBS) v2.0 score: 3].”
> “If these patients progress, liver-directed treatment modalities, anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.1-19"></a>

### Tebentafusp: NICE recommendation and clinical findings

> “Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.”
> “Clinical trial evidence suggests that tebentafusp could increase how long people live and how long they have before their cancer gets worse compared with usual treatment.”

Source: [NICE technology appraisal guidance TA1027, recommendations (2025)](https://www.nice.org.uk/guidance/ta1027/chapter/1-Recommendations)

<a id="topic-2.2.2.1.1-20"></a>

### Tebentafusp: CADTH recommendation, clinical findings, and inpatient monitoring for initial doses

> “The CADTH pCODR Expert Review Committee (pERC) recommends that tebentafusp be reimbursed for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the first-line setting”
> “Tebentafusp was associated with a risk of cytokine release syndrome and dermatological adverse events. pERC acknowledged that while not insignificant, these adverse events are transient and manageable with monitoring in an inpatient setting for initial doses, supportive care, and dose adjustment.”
> “According to the clinical expert consulted by CADTH, the first 3 to 4 infusions of tebentafusp are associated with a risk of cytokine release syndrome which requires inpatient monitoring in an experienced institution and management by a specialist physician experienced in the use of tebentafusp. Subsequent infusions may be performed in community clinic setting.”
> “pERC discussed the indirect treatment comparison (ITC) submitted by the sponsor: an unanchored matching-adjusted indirect comparison (MAIC) of tebentafusp relative to ipilimumab plus nivolumab. pERC noted that while a statistically significant improvement in OS and progression-free survival (PFS) for tebentafusp was demonstrated, the results of the ITCs stem from highly uncertain evidence due to limitations that impact the internal and external validity, despite the various adjustments.”
> “The preparation of tebentafusp is complex and intense and will require considerable Pharmacy resources to prepare each dose.”

Source: [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
